Their data showed that 56% (30/53) of patients with r/r B-cell acute lymphoblastic leukemia (B-ALL) developed coagulopathy after receiving split infusions of anti-CD19 CAR-T cells. This evidence concerns the gene CD19 and acute lymphoblastic leukemia.